Efficacy and Safety of endoscopic ultrasound-guided ethanol ablation therapy for pancreatic neuroendocrine tumors: A Pilot Study
- Conditions
- Pancreatic neuroendocrine tumor
- Registration Number
- JPRN-UMIN000018834
- Lead Sponsor
- Okayama University Hospital
- Brief Summary
A total of five patients were treated. The median size of the tumor was 10 mm (range 7-14). Of the five patients, three underwent an additional session. The median volume of ethanol injection per session was 0.8 (range: 0.3-1.0) mL, and the total was 1.0 (0.9-1.8) mL. Complete ablation at 1 month was achieved in 4 of the 5 tumors (80%). During one year of follow-up, none of the patients reported any procedure-related adverse events, and no malignancy or lymph node metastasis was noted.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 5
Not provided
1)Severe allergy history against medical drug 2)Allergy for contrast medium 3)Allergy for ethanol 4)Cases that could not visualize or puncture by using EUS 5)Cases that were diagnosed NEC from a core biopsy specimen obtained by EUS-FNA(WHO2010 classification) 6)Located near the main pancreatic duct 7)PT<=50% or INR>=1.5 8)PLT<=50,000/uL 9)eGFR<=30 mL/min 10)Patients who administered more than 2 anti-thrombotic agent 11)Patients with performance status 2-4. 12)Patients with poor prognosis (less than 3-year) 13)Age<20 14)Patients without informed consent 15)Patients who are judged inappropriate by chief medical examiner
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method